Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jandeleit

Showing results (21-30 of 190) with videos related to

Pageof 19
Sort By:
Journal of the American Heart Association|December 31, 2021
Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor Dapagliflozin Stabilizes Diabetes-Induced Atherosclerotic Plaque InstabilityYung-Chih Chen, Karin Jandeleit-Dahm, Karlheinz Peter
Clinical and Experimental Pharmacology & Physiology|February 23, 2008
The AGE/RAGE axis in diabetes-accelerated atherosclerosisKarin Jandeleit-Dahm, Anna Watson, Aino Soro-Paavonen
Nature Reviews. Cardiology|January 13, 2025
Atherosclerosis in diabetes mellitus: novel mechanisms and mechanism-based therapeutic approachesAbdul Waheed Khan, Karin A M Jandeleit-Dahm
PPAR Research|March 27, 2012
The renoprotective actions of peroxisome proliferator-activated receptors agonists in diabetesM C Thomas, K A Jandeleit-Dahm, C Tikellis
Clinical and Experimental Pharmacology & Physiology|May 1, 1992
Mesenteric vascular angiotensin-converting enzyme is increased in experimental diabetes mellitusK Jandeleit, J Rumble, B Jackson, et al.
Clinical and Experimental Pharmacology & Physiology|May 1, 1992
Mesenteric resistance and brain microvascular angiotensin-converting enzyme in the spontaneously hypertensive ratK Jandeleit, R Perich, B Jackson, et al.
Annals of the New York Academy of Sciences|July 23, 2005
Advanced glycation end products in diabetes-associated atherosclerosis and renal disease: interventional studiesKarin A Jandeleit-Dahm, Markus Lassila, Terri J Allen
Kidney International|September 17, 2005
Targets to retard the progression of diabetic nephropathyMark E Cooper, Karin Jandeleit-Dahm, Merlin C Thomas
Frontiers in Endocrinology|June 14, 2013
Diabetes alters activation and repression of pro- and anti-inflammatory signaling pathways in the vasculatureElyse Di Marco, Stephen P Gray, Karin Jandeleit-Dahm
Cardiovascular & Hematological Disorders Drug Targets|January 1, 2010
Cardiovascular disease: what's all the AGE/RAGE about?Drazenka P Barlovic, Merlin C Thomas, Karin Jandeleit-Dahm
Pageof 19

Showing results (21-30 of 190) with videos related to

Sort By:
Pageof 19
Journal of the American Heart Association|December 31, 2021
Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor Dapagliflozin Stabilizes Diabetes-Induced Atherosclerotic Plaque InstabilityYung-Chih Chen, Karin Jandeleit-Dahm, Karlheinz Peter
Clinical and Experimental Pharmacology & Physiology|February 23, 2008
The AGE/RAGE axis in diabetes-accelerated atherosclerosisKarin Jandeleit-Dahm, Anna Watson, Aino Soro-Paavonen
Nature Reviews. Cardiology|January 13, 2025
Atherosclerosis in diabetes mellitus: novel mechanisms and mechanism-based therapeutic approachesAbdul Waheed Khan, Karin A M Jandeleit-Dahm
PPAR Research|March 27, 2012
The renoprotective actions of peroxisome proliferator-activated receptors agonists in diabetesM C Thomas, K A Jandeleit-Dahm, C Tikellis
Clinical and Experimental Pharmacology & Physiology|May 1, 1992
Mesenteric vascular angiotensin-converting enzyme is increased in experimental diabetes mellitusK Jandeleit, J Rumble, B Jackson, et al.
Clinical and Experimental Pharmacology & Physiology|May 1, 1992
Mesenteric resistance and brain microvascular angiotensin-converting enzyme in the spontaneously hypertensive ratK Jandeleit, R Perich, B Jackson, et al.
Annals of the New York Academy of Sciences|July 23, 2005
Advanced glycation end products in diabetes-associated atherosclerosis and renal disease: interventional studiesKarin A Jandeleit-Dahm, Markus Lassila, Terri J Allen
Kidney International|September 17, 2005
Targets to retard the progression of diabetic nephropathyMark E Cooper, Karin Jandeleit-Dahm, Merlin C Thomas
Frontiers in Endocrinology|June 14, 2013
Diabetes alters activation and repression of pro- and anti-inflammatory signaling pathways in the vasculatureElyse Di Marco, Stephen P Gray, Karin Jandeleit-Dahm
Cardiovascular & Hematological Disorders Drug Targets|January 1, 2010
Cardiovascular disease: what's all the AGE/RAGE about?Drazenka P Barlovic, Merlin C Thomas, Karin Jandeleit-Dahm
Pageof 19